NEW WEBSITE We would like to invite you to a sneak peak of our new website before it goes live. Visit the new site

SciLifeLab The Svedberg seminar series 2014-04-25 EXTRA SEMINAR!

Jörg D. Hoheisel

Head, Functional Genome Analysis 
Deutsches Krebsforschungszentrum
, Heidelberg, Germany

Jörg Hoheisel heads the Division of Functional Genome Analysis and is chairman of the Scientific Council of the German Cancer Research Center in Heidelberg. His research objectives are an understanding of the realisation of cellular function from genetic information, with a current focus in proteomics. Next to his academic work, Jörg co-founded five companies; another three were formed by former group members independently.

Prior to joining DKFZ in 1993, Jörg worked for five years at the Imperial Cancer Research Fund in London, the initial two years funded by an EMBO fellowship. Previously, he had studied molecular biology at Constance University in Germany; his diploma and PhD were about topologically induced DNA-structures and the functioning of DNA-binding enzymes.

Affinity-based assays for personalised proteomics in cancer research

In recent years, clinical genome sequencing has become possible. However, much disease-relevant regulation and activity occurs at the protein level. Consequently, we are aiming at a personalised characterisation of disease-specific protein isoforms, utilising a newly developed technique. Genes are copied onto a microarray from a tissue’s RNA/cDNA by on-chip PCR amplification, using primer pairs that are attached at distinct array locations. The DNA acts as template for an in situ cell-free expression, yielding a microarray that presents the protein content of a particular tissue of an individual person. Our objectives are the detection of disease-related protein variations, development of personalised diagnostics and the identification of therapeutically relevant protein interactions with other proteins, nucleic acids and small chemical compounds. Knowledge about protein isoforms in individual patients will be critical for therapeutic approaches that target disease-relevant protein conformations, while leaving the molecules in healthy tissues unaffected.

Host: Masood Kamali-Moghaddam